Clinical Content & Reports

Monthly Drug Pipeline & Clinical Update - June 2023

July 14, 2023

Capital Rx

Highlights

  • Three key new approvals, including Inpefa™ (sotagliflozin), Vevye™ (cyclosporine), and Lodoco® (colchicine).
  • Several notable expanded indications, including Linzess® (linaclotide), Lynparza® (olaparib), and Jardiance® (empagliflozin), among others.
  • Two generic launches: Prezista® and Noxafil®
  • Update Drug Recall Report: CLICK HERE to review.

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications and products in the pipeline. Read on to review our June 2023 Monthly Drug Update!

Key New Drug Approvals

Inpefa™ (sotagliflozin) tablets

Approval Date: 05/26/2023 - CLICK HERE for the press release

Indication: Reduce the risk of cardiovascular death, hospitalization for certain patients with heart failure

Cost*: $24 per tablet

Key Considerations:

Vevye™ (cyclosporine) ophthalmic solution

Approval Date: 05/30/2023 - CLICK HERE for the press release

Indication: Signs and symptoms of dry eye disease

Cost*: TBD

Key Considerations:

Lodoco® (colchicine) tablets

Approval Date: 06/20/2023 - CLICK HERE for the press release

Indication: Reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease

Cost*: TBD

Key Considerations:

Notable Expanded Indications

Linzess® (linaclotide) - expanded to be indicated for the treatment of functional constipation in children and adolescents 6 to 17 years of age

Bylvay™ (odevixibat) - expanded to be indicated for the treatment of cholestatic pruritis in patients aged 12 months and older with Alagille syndrome

Lynparza® (olaparib) - expanded to be used in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer

Jardiance® (empagliflozin) - expanded to be indicated in addition to diet and exercise to improve blood sugar control in children 10 years of age and older with type 2 diabetes

Synjardy® (empagliflozin/metformin) - expanded to be indicated in addition to diet and exercise to improve blood sugar control in children 10 years of age and older with type 2 diabetes

Generic Launches

Prezista® (darunavir 600mg, 800mg) tablet for treatment of HIV infections

Noxafil® (posaconazole 300mg/16.7mL) IV solution to treat or prevent fungal infections

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.

--------

* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights